Epigenetic mechanisms in breast cancer therapy and resistance

The majority of breast cancers express the estrogen receptor (ERα) and agents targeting this pathway represent the main treatment modality. Endocrine therapy has proven successful in the treatment of hormone-responsive breast cancer since its early adoption in the 1940s as an ablative therapy. Unfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Martinez, Liliana, Zhang, Yusheng, Nakata, Yuichiro, Chan, Ho Lam, Morey, Lluis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979820/
https://www.ncbi.nlm.nih.gov/pubmed/33741974
http://dx.doi.org/10.1038/s41467-021-22024-3
_version_ 1783667345019895808
author Garcia-Martinez, Liliana
Zhang, Yusheng
Nakata, Yuichiro
Chan, Ho Lam
Morey, Lluis
author_facet Garcia-Martinez, Liliana
Zhang, Yusheng
Nakata, Yuichiro
Chan, Ho Lam
Morey, Lluis
author_sort Garcia-Martinez, Liliana
collection PubMed
description The majority of breast cancers express the estrogen receptor (ERα) and agents targeting this pathway represent the main treatment modality. Endocrine therapy has proven successful in the treatment of hormone-responsive breast cancer since its early adoption in the 1940s as an ablative therapy. Unfortunately, therapeutic resistance arises, leading to disease recurrence and relapse. Recent studies increased our understanding in how changes to the chromatin landscape and deregulation of epigenetic factors orchestrate the resistant phenotype. Here, we will discuss how the epigenome is an integral determinant in hormone therapy response and why epigenetic factors are promising targets for overcoming clinical resistance.
format Online
Article
Text
id pubmed-7979820
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-79798202021-04-16 Epigenetic mechanisms in breast cancer therapy and resistance Garcia-Martinez, Liliana Zhang, Yusheng Nakata, Yuichiro Chan, Ho Lam Morey, Lluis Nat Commun Perspective The majority of breast cancers express the estrogen receptor (ERα) and agents targeting this pathway represent the main treatment modality. Endocrine therapy has proven successful in the treatment of hormone-responsive breast cancer since its early adoption in the 1940s as an ablative therapy. Unfortunately, therapeutic resistance arises, leading to disease recurrence and relapse. Recent studies increased our understanding in how changes to the chromatin landscape and deregulation of epigenetic factors orchestrate the resistant phenotype. Here, we will discuss how the epigenome is an integral determinant in hormone therapy response and why epigenetic factors are promising targets for overcoming clinical resistance. Nature Publishing Group UK 2021-03-19 /pmc/articles/PMC7979820/ /pubmed/33741974 http://dx.doi.org/10.1038/s41467-021-22024-3 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Perspective
Garcia-Martinez, Liliana
Zhang, Yusheng
Nakata, Yuichiro
Chan, Ho Lam
Morey, Lluis
Epigenetic mechanisms in breast cancer therapy and resistance
title Epigenetic mechanisms in breast cancer therapy and resistance
title_full Epigenetic mechanisms in breast cancer therapy and resistance
title_fullStr Epigenetic mechanisms in breast cancer therapy and resistance
title_full_unstemmed Epigenetic mechanisms in breast cancer therapy and resistance
title_short Epigenetic mechanisms in breast cancer therapy and resistance
title_sort epigenetic mechanisms in breast cancer therapy and resistance
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979820/
https://www.ncbi.nlm.nih.gov/pubmed/33741974
http://dx.doi.org/10.1038/s41467-021-22024-3
work_keys_str_mv AT garciamartinezliliana epigeneticmechanismsinbreastcancertherapyandresistance
AT zhangyusheng epigeneticmechanismsinbreastcancertherapyandresistance
AT nakatayuichiro epigeneticmechanismsinbreastcancertherapyandresistance
AT chanholam epigeneticmechanismsinbreastcancertherapyandresistance
AT moreylluis epigeneticmechanismsinbreastcancertherapyandresistance

Ejemplares similares